PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193436
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1193436
Achondrogenesis Market size was valued at USD 1,807.1 Million in 2022, expanding at a CAGR of 4.4% from 2023 to 2030.
Achondrogenesis is defined by the excessive shortening of the legs and arms in comparison to the trunk as a result of faulty rib, vertebra, and other skeletal anomalies in growth and development. Infants are typically affected by chondrogenesis, which frequently causes them to pass away before birth.
Market Dynamics
The prevalence of hereditary genes, which includes achondrogenesis among others, is rising globally, and as a result, the market is anticipated to experience significant growth over the forecast period. Achondrogenesis is defined by the excessive shortening of the legs and arms in comparison to the trunk as a result of faulty rib, vertebra, and other skeletal anomalies in growth and development. Flat face, anteverted nares, frontal bossing, fatal skeletal dysplasia, and aberrant endochondral ossification are only a few of the illness signs linked to chondrogenesis. According to the NORD (National Organization for Rare Disease), achondrogenesis affects one in 40,000-60,000 newborns.
Additionally, the market is growing as a result of rising research efforts and the high reliance of patients on supportive and palliative care. Additionally, growing healthcare costs and technology developments for disease diagnostics present potential prospects for the industry. However, the Achondrogenesis market may be hampered by factors such as a lack of effective treatment options, high illness detection costs, and a shortage of qualified specialists. Because hereditary illnesses are becoming more common and governments are becoming more concerned about the health of newborns, Asia-Pacific is predicted to hold the biggest market share.
Segmentation Analysis:
The Global Achondrogenesis Market is segmented on the basis of Type, Diagnosis, End User, and Region.
The market is split into three categories based on Type: Type IA, Type IB, and Type II. The Type IA segment dominates the market. Various symptoms associated with achondrogenesis includes flat face, anteverted nares, which is mainly contributing to segment growth.
The market is segmented into four categories based on Diagnosis: physical examination, molecular genetic testing, and biochemical testing. The genetic testing segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to a rise in the number of genetic disorders across the globe.
The market is segmented into five categories based on End User: clinics, hospitals, diagnostic centers, academic research, and others. The diagnostic centers segment dominates the market and is likely to maintain its dominance during the forecast period. This is partly due to an increase in the clinical diagnostic activities, boosting the segment growth.
Competitive Landscape:
The worldwide market for Achondrogenesis is highly fragmented in nature which consist of large and small-sized market players with few large dominating the global market share. The companies in market emphasize on adopting aggressive strategies to reach out large consumer base. Some of the primary techniques used by corporations to strengthen their reach and expand their market share include new research projects, partnerships, distribution network development, R&D spending, and mergers and acquisitions.
For instance, in November 2022, Illumina Inc., and Genetic Alliance introduced $120 Million global initiative to increase equity and improve outcomes for families impacted by genetic disease.
Key features of the study:
This proposed research study on Achondrogenesis market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2023-2030), considering 2022 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Achondrogenesis market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Achondrogenesis market
Impact of COVID-19 on Achondrogenesis market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Achondrogenesis market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Achondrogenesis market, we have also included competitive landscape and key innovator analysis for the Achondrogenesis market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Achondrogenesis market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new launch, research & development, regional expansion of major participants involved in the market on global as well as regional level.
The global Achondrogenesis market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL ACHONDROGENESIS MARKET KEY PLAYERS
Thermo Fisher Scientific Inc.
CooperSurgical, Inc.
Illumina, Inc
Siemens
FUJIFILM Holdings Corporation
Koninklijke Philips N.V.
Stryker
TOSHIBA CORPORATION
Invivoscribe, Inc.
Abbott
INVITROGEN CORPORATION
Bio-Rad Laboratories, Inc.
Agilent Technologies, Inc.
Natera Inc.
Cepheid
ELITech Group
Autogenomics,
F. Hoffmann-La Roche AG
GLOBAL ACHONDROGENESIS MARKET, BY TYPE
Type IA
Type IB
Type II
GLOBAL ACHONDROGENESIS MARKET, BY DIAGNOSIS
Physical examination
Molecular genetic testing
Biochemical testing
GLOBAL ACHONDROGENESIS MARKET, BY END USER
Clinics
Hospitals
Diagnostic Centers
Academic Research
Others
GLOBAL ACHONDROGENESIS MARKET, BY REGION
North America
The U.S.
Canada
Europe
Germany
France
Italy
Spain
United Kingdom
Russia
Netherlands
Sweden
Poland
Rest of Europe
Asia Pacific
India
China
South Korea
Japan
Australia
Thailand
Indonesia
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
United Arab Emirates
Israel
Turkey
Algeria
Egypt
Rest of MEA